Therachon

company

About

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$60M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Close

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$100M
Therachon has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Aug 9, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 9, 2018 Series B $60M 2 Detail
Jan 6, 2017 Series A $5M 2 Detail
Sep 30, 2015 Series A $35M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Therachon is funded by 2 investors. Inserm Transfert Initiative and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Inserm Transfert Initiative Series B
Versant Ventures Series B